General Information of Drug Combination (ID: DCY5WX6)

Drug Combination Name
Nebivolol Metoprolol
Indication
Disease Entry Status REF
High Blood Pressure Phase 1 [1]
Component Drugs Nebivolol   DM7F1PA Metoprolol   DMOJ0V6
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Nebivolol
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [2]
Nebivolol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Antagonist [5]
------------------------------------------------------------------------------------
Nebivolol Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Metoprolol
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [3]
Angina pectoris BA40 Approved [3]
Cardiac arrest MC82 Approved [3]
Chronic heart failure BD1Z Approved [3]
Hypertension BA00-BA04 Approved [4]
Malignant essential hypertension BA00 Approved [3]
Myocardial infarction BA41-BA43 Approved [3]
Obesity 5B81 Approved [3]
Ventricular fibrillation BC71.1 Approved [3]
Metoprolol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Antagonist [9]
------------------------------------------------------------------------------------
Metoprolol Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [10]
------------------------------------------------------------------------------------
Metoprolol Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [11]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [12]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [13]
------------------------------------------------------------------------------------
Metoprolol Interacts with 5 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Renin (REN) OT52GZR2 RENI_HUMAN Decreases Expression [14]
Collagen alpha-1(III) chain (COL3A1) OTT1EMLM CO3A1_HUMAN Increases Expression [15]
Ryanodine receptor 2 (RYR2) OT0PF19E RYR2_HUMAN Increases Activity [16]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Affects Response To Substance [17]
G protein-coupled receptor kinase 4 (GRK4) OTUU8V2S GRK4_HUMAN Affects Response To Substance [18]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Hypertension DC5SYJY N. A. Phase 1 [19]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01049009) The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7246).
3 Metoprolol FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 553).
5 Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27.
6 Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.
7 Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. Drug Metab Dispos. 2016 Nov;44(11):1828-1831.
8 beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFB and AP-1. Cancer Biol Ther. 2010 Jul 1;10(1):19-29.
9 Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
10 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
11 Chemical stability-indicating HPLC study of fixed-dosage combination containing metoprolol tartrate and hydrochlorothiazide.
12 The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715.
13 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14 Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S124-9.
15 Modelling cardiac fibrosis using three-dimensional cardiac microtissues derived from human embryonic stem cells. J Biol Eng. 2019 Feb 13;13:15. doi: 10.1186/s13036-019-0139-6. eCollection 2019.
16 Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation. 2003 May 20;107(19):2459-66. doi: 10.1161/01.CIR.0000068316.53218.49. Epub 2003 May 12.
17 Beta-2-adrenergic receptor polymorphisms and changes in lipids induced by metoprolol. Pharmacology. 2007;80(4):279-85. doi: 10.1159/000106554. Epub 2007 Aug 2.
18 G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens. 2009 Mar;22(3):332-8. doi: 10.1038/ajh.2008.341. Epub 2009 Jan 1.
19 ClinicalTrials.gov (NCT01041287) Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells